Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
EntidadUAM. Departamento de Medicina Preventiva y Salud Pública y Microbiología
EditorBioMed Central Ltd.
Fecha de edición2017-01-01
10.1186/s12872-017-0591-5BMC Cardiovascular Disorders 17.1 (2017): 160
Financiado porWriting support was provided by Gary Male, PhD from Oxford Pharma Genesis, Oxford, UK and was funded by AstraZeneca
Versión del editorhttps://doi.org/10.1186/s12872-017-0591-5
MateriasAtherogenic dyslipidemia; Cardiovascular disease; Epidemiology; Risk factors/global assessment; Medicina
Derechos© The Author(s). 2017
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.
Background: Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of highdensity lipoprotein cholesterol. Methods: This cross-sectional observational study assessed the prevalence of two atherogenic dyslipidemia markers, high triglyceride levels and low high-density lipoprotein cholesterol levels, in the study population from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; N = 7641; of whom 51.6% were female and 95.6% were White/Caucasian). The EURIKA population included European patients, aged at least 50 years with at least one cardiovascular risk factor but no history of cardiovascular disease. Results: Over 20% of patients from the EURIKA population have either triglyceride or high-density lipoprotein cholesterol levels characteristic of atherogenic dyslipidemia. Furthermore, the proportions of patients with one of these markers were higher in subpopulations with type 2 diabetes mellitus or those already calculated to be at high risk of cardiovascular disease. Approximately 55% of the EURIKA population who have markers of atherogenic dyslipidemia are not receiving lipid-lowering therapy. Conclusions: A considerable proportion of patients with at least one major cardiovascular risk factor in the primary cardiovascular disease prevention setting have markers of atherogenic dyslipidemia. The majority of these patients are not receiving optimal treatment, as specified in international guidelines, and thus their risk of developing cardiovascular disease is possibly underestimated
Google Scholar:Halcox, Julian P. - Banegas Banegas, José Ramón - Roy, Carine - Dallongeville, Jean - De Backer, Guy - Guallar, Eliseo - Perk, Joep - Hajage, David - Henriksson, Karin M. - Borghi, Claudio
Lista de colecciones del ítem
Mostrando ítems relacionados por título, autor, creador y materia.
Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe
C-reactive protein levels in patients at cardiovascular risk: EURIKA study
Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study Guallar, Eliseo; Banegas Banegas, José Ramón; Blasco-Colmenares, Elena; Jiménez, Francisco Javier Gómez; Dallongeville, Jean; Halcox, Julian PJ J; Borghi, Claudio; Massó-González, Elvira L.; Tafalla, Mónica; Perk, Joep; De Backer, Guy G.; Steg, Philippe Gabriel; Rodríguez Artalejo, Fernando